Direct comparison
Tirzepatid vs Retatrutid
How Tirzepatid and Retatrutid compare on mechanism, evidence and legal status — factual, no recommendations.
| Tirzepatid | Retatrutid | |
|---|---|---|
| Class | GLP-1 analog | GLP-1 analog |
| Evidence level | clinically established | early clinical studies |
| Legal status (DE) | prescription-only | not approved |
| WADA-listed | No | No |
| Molar mass | 4813.45 Da | 4731.33 Da |
| Studies cited | 3 | 2 |
| Research areas | Metabolism | Metabolism |
Tirzepatid
Tirzepatide is a dual agonist at GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors.
Full Tirzepatid profileRetatrutid
Retatrutide is a triple agonist at GIP, GLP-1 and glucagon receptors (GGG agonist).
Full Retatrutid profileImportant notice
This site is intended solely for factual, scientifically oriented information about peptides. It does not constitute medical advice, does not replace a consultation with a doctor and contains no recommendations for use in humans.
This site does not sell any substances and names no sources for unapproved substances. For medical questions, please consult qualified medical professionals.